Corvia Medical, Inc.

Corvia Medical, Inc. is revolutionizing the treatment of heart
failure (HF) with a novel transcatheter structural heart device.

[Corvia Medical, Inc. @corviamedical]

Corvia is proud to support the @MedUnivSC #charlestonHFpEF Conference from July 19-21. Heart failure with preserved ejection fraction (#HFpEF) is a hot topic — join course director @LitwinSheldon & other esteemed faculty to discover why! #heartfailure #atrialshunt #cardiotwitter

[Corvia Medical, Inc. @corviamedical]

#CSIFrankfurt2024 is here! Don't miss today's session on #Interatrialshunt therapy at 16:15 CEST. With two #atrialshunt randomized trials now complete, come hear @amin_polzin discuss why the #Corvia Atrial Shunt holds promise for #HFpEF patients!

#cardiotwitter #structuralheart

[Corvia Medical, Inc. @corviamedical]

#CSIFrankfurt2024 is almost here! Don't miss Wednesday's #Interatrialshunt Workshop where @amin_polzin from @UniklinikDUS will share lessons learned from REDUCE LAP-HF II & how these findings are being validated in #RESPONDERHF. #atrialshunt #HFpEF #cardiotwitter #heartfailure

[Corvia Medical, Inc. @corviamedical]

Jimmy's story gives us confidence we are on the right path with our confirmatory trial #RESPONDERHF. Learn more at https://t.co/u7lE8N8TuO.
@LitwinSheldon #HFpEF #atrialshunt

Caution: Investigational device, limited by US law to investigational use.
https://t.co/Geb15N48Ty

[Corvia Medical, Inc. @corviamedical]

Great interview with @HFpEF regarding the favorable long-term effects of an #atrialshunt observed in REDUCE LAP-HF II #heartfailure patients.

[JAMA Cardiology @JAMACardio]

Interview with Sanjiv J. Shah, MD, author of "Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial" hosted by James E. Udelson, MD. @HFpEF https://t.co/zKvgy0sfFd

[Corvia Medical, Inc. @corviamedical]

What is the long-term effect of an #atrialshunt? Recently published data in @JAMACardio by @RBPatelMD shows favorable effects of the Corvia Atrial Shunt on cardiac structure & function in #heartfailure patients. #HFpEF #cardiotwitter
https://t.co/wMGwBUNxtc

[Corvia Medical, Inc. @corviamedical]

During #NationalNursesWeek, we extend our deepest appreciation to all the incredible #HeartFailure nurses. Your expertise, empathy, and dedication are instrumental in improving life for millions. Thank you for being the heartbeat of compassionate care. #NursesWeek2024 #Corvia

[Corvia Medical, Inc. @corviamedical]

Happy #NationalNursesDay to all the dedicated heart failure nurses! Your unwavering commitment & compassion make a significant impact on the lives of #heartfailure patients. Your dedication makes all the difference.
#NursesMakeTheDifference #GratefulHeart #NursesWeek2024 #Corvia

[Cardiac Interventions Today @cardiacinterv]

Corvia Highlights Importance of Patient Selection in RESPONDER-HF Atrial Shunt Trial | @corviamedical https://t.co/hgfhiDyyUP

[Corvia Medical, Inc. @corviamedical]

We continue to learn which #heartfailure patients may benefit most from #atrialshunt therapy. Recent RELIEVE-HF data reinforces the importance of patient selection and suggests we are on the right path with #RESPONDERHF to confirm optimal #HFpEF patients.
https://t.co/IXJ4m6iofR

[Corvia Medical, Inc. @corviamedical]

It's the last day of #ACC24, but there's still time time to come learn about #atrialshunt therapy and which #HFpEF patients might from participating in the #RESPONDERHF trial. Come see us at booth 3338!

#CardioTwitter #HeartFailure

[Corvia Medical, Inc. @corviamedical]

Congratulations to @vijayswarup and the @ArizonaRhythm team for the great coverage of their REDUCE LAP-HF II patient and their ongoing work to bring #atrialshunt therapy to #heartfailure patients in AZ. https://t.co/3LFiheAIBj

#HFpEF #CardioTwitter #clinicaltrials #RESPONDERHF

[Corvia Medical, Inc. @corviamedical]

FACT: #HeartFailure affects 6.2 million people in the US—this may include someone you love.

Join #Corvia this #HeartMonth to prioritize #hearthealth awareness. Your knowledge could change a life. Learn more about heart failure here: https://t.co/ZTgm8b6Pok

#twittercardio

[Corvia Medical, Inc. @corviamedical]

February is American #HeartMonth ❤️, a time to raise awareness about heart health and cardiovascular disease. #CorviaMedical is proud to be part of the solution to improve the lives of millions of people who suffer from heart disease.
#HeartMonth2024 #cardiotwitter #corvia

[Corvia Medical, Inc. @corviamedical]

As the year comes to a close, we want to take a moment to express our #gratitude to our investigators, customers, and partners for their support throughout the year. May this #holidayseason bring you love, light, and laughter, and the New Year bring much #prosperity & #success.

[Corvia Medical, Inc. @corviamedical]

We hope to see you in Wiesbaden, Germany at #CSIFocusDHF! Thanks in advance to Prof. Rudin Pistulli who will present his experience with the #Corvia Atrial Shunt and to @CSIcongress for its continued focus on the potential of #atrialshunt therapy for #heartfailure. #CSIDHF

[Corvia Medical, Inc. @corviamedical]

#Heartlive in Munich begins later this week! Hear from the experts - Profs. Ulf Landmesser, Martin Bergmann, and Mirjam Keßler - at our symposium on #atrialshunt therapy for #HFpEF. Stop by booth #13 and learn about our confirmatory trial #RESPONDERHF. #Corvia #heartfailure

[Corvia Medical, Inc. @corviamedical]

Congratulations to @vikjag45 and the team at @WVUMedicine for leading the way and being the first center in West Virginia to enroll a patient in the #RESPONDERHF trial. Together, we are working to give #heartfailure patients another reason to hope. #HFpEF #atrialshunt

[Corvia Medical, Inc. @corviamedical]

In “BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction”, @HFpEF shares imperfections in using NPs in #HFpEF.

Corvia's #RESPONDERHF #atrialshunt trial includes these HFpEF pts with low NPs who might otherwise be overlooked.

https://t.co/gW2iwHhX5S

[Corvia Medical, Inc. @corviamedical]

#Heartfailure expert and PI for Corvia's RESPONDER-HF trial, @LitwinSheldon from @MedUnivSC describes the unmet need of #HFpEF and how #atrialshunt therapy, being evaluated through #RESPONDERHF, could be a game-changer for patients & clinicians. #clinicaltrials #CardioTwitter

[Medical Device News Magazine @MedDeviceNews1]

A Lifesaving Shunt in the Heart? | By Dr. Sheldon Litwin "Approximately 60 study sites worldwide are participating in RESPONDER-HF, a randomized clinical trial of the Corvia Atrial Shunt." Read what this expert has to say. https://t.co/6kbdlWMQtD